Products Description


Product name




Each capsule contains :

Fluconazole ……… ……………….. 150 mg




* Aspergillus flavus                                       * Aspergillus fumigatus

* Blastomyces dermatitidis                            * Candida albicans

* Candida kefyr                                               *Candida tropicalis

* Candidemia                                                  * Candidiasis

* Candidiasis prophylaxis(*)                           * Candiduria

* Coccidioides immitis                                   * Coccidioidomycosis(*)

* Coccidioidomycosis prophylaxis(*)             * Cryptococcosis prophylaxis(*)

* Cryptococcus neoformans                           * Esophageal candidiasis

* Fungal prophylaxis                                      * Histoplasma capsulatum

* Histoplasmosis prophylaxis(*)                     * Meningitis

* Oropharyngeal candidiasis (thrush)             * Peritonitis

* Pneumonia                                                   * Torulopsis glabrata

* Urinary tract infection (UTI)  * Vulvovaginal candidiasis


Dosage & Administration


Oropharyngeal or esophageal candidiasis :

ADULTS: PO/IV 200 mg first day, followed by 100 mg qd thereafter for minimum of 2 wk for oropharyngeal candidiasis or 3 wk for esophageal candidiasis. CHILDREN: PO/IV 6 mg/kg on first day, followed by 3 mg/kg qd thereafter for minimum of 2 wk for oropharyngeal candidiasis or 3 wk (at least 2 weeks after symptom resolution) for esophageal candidiasis.

Vaginal candidiasis :

ADULTS: PO 150 mg single dose.

Prevention of candidiasis in bone marrow transplant :

ADULTS: PO/IV 400 mg once daily; in patients with anticipated severe granulocytopenia (< 500 neutrophils/mm3) start fluconazole several days before anticipated onset and continue 7 days after neutrophil count rises > 1000 cells/mm3.

Cryptococcal meningitis :

ADULTS: PO/IV 400 mg first day, followed by 200 mg qd thereafter (400 mg may be used) for 10 to 12 wk after CSF culture is negative for initial meningitis; 200 mg qd for suppression of relapse of cryptococcal meningitis.

Candidemia and disseminated candida infections :

CHILDREN: PO/IV 6 to 12 mg/kg/day.

Cryptococcal meningitis 12 mg/kg on first day, followed by 6 mg/kg/day (or 12 mg/kg/day based on medical judgment of patient's response). Recommended duration is 10 to 12 weeks after CSF becomes culture negative.

Suppression of relapse in AIDS patients– 6 mg/kg/day. NEONATES: Experience is limited to pharmacokinetic studies in premature newborns. Prolonged half-life has been noted. These children, in the first 2 wk of life, should receive the same mg/kg dosage as other children, but administered every 72 hr. After the first 2 wk, dose once daily.




Pack of 1 blisters X 1 capsule.

Hospital packs of different sizes.



Copyright © 2008 biopharm-ye. All rights reserved